Sichuan Biokin Pharmaceutical's (SHA:688506) T-Bren for injection (BL-M07D1) is included in the Chinese drug administration's list of breakthrough therapy drugs, according to a Shanghai bourse filing on Wednesday.
The drug is used for the treatment of patients with gastroesophageal junction adenocarcinoma who have failed prior first-line anti-HER2 therapy and standard first-line chemotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments